in vivo– tag –
-
LNP Design Innovations Enable Extrahepatic Nucleic Acid Delivery: Paving Way for Mucosal Administration Routes
MDPI Switzerland Overview Recent breakthroughs in lipid nanoparticle (LNP) design, driven by altered formulation composition and chemical modification of ionizable lipids, are enabling organ-selective nucleic acid delivery beyond the liv... -
VERVE-101 Achieves 53-69% LDL-C Reduction in Lipid Disorder Trials, Accelerating LNP-Based Gene Editing Therapeutics
PMC (Part of MDPI) Switzerland Overview VERVE-101, an in vivo base editing therapy targeting PCSK9 via mRNA-LNP delivery, has progressed to clinical trials (NCT05398029) for lipid disorders, showing significant LDL-C reductions of 53% to... -
Bispecific Antibody-Conjugated Lipid Nanoparticles Achieve Cell-Specific mRNA Delivery, Overcoming Liver Tropism
ACS Publications USA Overview Researchers have developed a bispecific antibody-conjugated lipid nanoparticle (TbsAb-LNP) platform designed for precise, cell-specific mRNA delivery, effectively circumventing the inherent liver tropism of ... -
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro... -
Complete Guide to Lipid Nanoparticles (LNP): Foundational Technology for Nucleic Acid Delivery Validated by mRNA Vaccine Success
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are nanoscale delivery vehicles designed to protect and deliver nucleic acids like mRNA and siRNA into cells, serving as the delivery platform for COVID-19 mRNA vaccines. LNPs o... -
FDA Clears Prime Medicine’s In Vivo Prime Editor for Wilson Disease, Setting Stage for 2027 Data
BioSpace USA Overview Prime Medicine has secured FDA Investigational New Drug (IND) clearance for PM577a, an in vivo Prime Editor designed to correct the H1069Q mutation in Wilson disease. This approval initiates a global Phase 1/2 clini... -
CuraCell Pursues Gentler Preconditioning and Reduced Manufacturing Costs for CC-38 TIL Therapy for Solid Tumors, Enhancing Patient Eligibility and Cost-Effectiveness
Clinical Leader USA Overview CuraCell is focusing on a gentler preconditioning regimen and reduced manufacturing costs for its CC-38 T cell therapy program, which utilizes patient-derived tumor-infiltrating lymphocytes (TILs) for solid t... -
Eli Lilly Acquires Kelonia and Orna Therapeutics as Investment in In Vivo Cell Therapies Surges, Aiming to Reduce Treatment Burden and Manufacturing Costs
DCAT Value Chain Insights USA Overview In vivo cell therapies, where the patient's body becomes the manufacturing site for cells like CAR T cells, are attracting substantial biopharmaceutical investment due to their potential to reduce t... -
Widespread Global Disparities in CAR T-Cell Therapy Access Highlighted; In Vivo CAR-T, Allogeneic Platforms, and Rapid Manufacturing Emerge as Potential Solutions
ASH Clinical News USA Overview Significant global disparities in CAR T-cell therapy access are attributed to high costs, manufacturing complexities, and limited healthcare infrastructure. Novel scientific strategies, including in vivo CA... -
Umoja Biopharma Secures FDA IND Clearance for UB-VV400, First-in-Industry CD22-Targeted In Vivo CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies
Umoja Biopharma (Press Release) USA Overview Umoja Biopharma has received FDA Investigational New Drug (IND) clearance for UB-VV400, a CD22-targeted in vivo CAR T cell therapy candidate for relapsed/refractory B-cell malignancies. This m...
